Photo credit: Dave Poland/PATH

We act as catalyst, facilitator, and convenor in the malaria vaccine community.

Through our partnerships, collaborations, and other activities, we make an imprint in the malaria vaccine development field, advancing the conversation in a number of areas, including the following: 

  • Product development partnerships
  • Vaccine approaches
  • Mosquito-feeding assays
  • Assay standardization
  • Global policy and regulatory arena 
Explore our research and development strategy.
Explore our preferred product characteristics.

 

Product development partnerships 

MVI plays a central role in helping to share lessons across product development partnerships (PDPs). We collaborate extensively with other PDPs and actively participate in a number of working groups across policy, access, financial, legal, advocacy, and clinical areas. 
 

Vaccine approaches

MVI has played a leading role in advancing the conversation in key areas in malaria vaccine development. As an active member of the Malaria Vaccine Funders Group, MVI was at the forefront of consultations, facilitated by the World Health Organization, that led to both the 2006 Malaria Vaccine Technology Roadmap and the expanded vision and goals of the 2013 edition. Our leadership ensured that the updated strategic goals of the roadmap included a focus on vaccines that reduce transmissionof the malaria parasite to enable elimination of the disease and eventual eradication. 
 

Mosquito-feeding assays 

MVI continues to explore approaches to measuring malaria transmission-blocking activity in both the laboratory and the field. Our work includes investigating advanced detection methods for measuring malaria transmission from humans to mosquitoes, and bridging the results obtained in laboratory settings to those obtained in the field. We are also keen to share what we have learned. In this regard, MVI provided support for a 2014 workshop in Yaoundé, Cameroon, to provide lab technicians and entomologists working on malaria research in Africa with hands-on training in the performance of the direct membrane-feeding assays.
 

Assay standardization 

MVI supports three assay reference centers, which offer critical resources to our program and the wider malaria community by testing samples to a uniform set of standards, allowing more objective, accurate comparisons of vaccines across platforms and thus accelerating development. Further, having readily accessible, high quality reagents available to the community is important to accelerate vaccine development activities. In light of this, MVI has supported the development of standardized reagents that can be used as controls in assays and for process development activities during vaccine manufacture.
 

Global policy and regulatory arena 

We have broken new ground in the policy and regulatory arena. Working closely with global partners, MVI mapped and continues to update the global pathway for the regulatory and policy process associated with the introduction of a malaria vaccine. The availability of World Health Organization (WHO) preferred product characteristics (PPCs) for malaria vaccines is helping to inform the development of an integrated product development plan that will start to define pathways for novel malaria vaccines going forward. 
 
In addition to using PPCs, we have also collaborated extensively with relevant WHO bodies. Defining the needs for each of these bodies and mapping out the optimal timing for engagement are critical success factors for the development of any new malaria vaccine. The relevant WHO bodies with which we have collaborated include the following: the Malaria Vaccine Advisory Committee (MALVAC); Malaria Policy Advisory Committee (MPAC); Joint Technical Expert Group (JTEG) on Immunization; Strategic Advisory Group of Experts (SAGE) on Immunization; Global Advisory Committee on Vaccine Safety (GACVS); Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC); and Expert Committee on Biological Standardization (ECBS).